{"title":"Long-term antibody response after COVID-19 vaccination in health care workers: A single centre study from Pakistan.","authors":"Fatima Kanani, Javeria Ejaz, Sabiha Anis, Mamoona Mushtaq","doi":"10.47391/JPMA.20351","DOIUrl":null,"url":null,"abstract":"<p><p>The retrospective cohort study was planned to determine long-term anti-spike immunoglobulin G levels after receiving coronavirus disease-2019 vaccination by healthcare workers. The study took place between June and July 2022 at the Indus hospital in Karachi. Healthcare workers who had previously screened negative to prevaccination Severe Acute Respiratory Syndrome Coronavirus 2 nucleocapsid antibodies were tested for post-vaccination Severe Acute Respiratory Syndrome Coronavirus 2 anti-spike immunoglobulin G levels using a quantitative assay. The test was also performed on the stored pre-vaccination samples of the subjects collected up to 18 months previously. Antibody levels in subjects without infection, with infection and with booster administration were compared. The median postvaccination anti-spike immunoglobulin G in infected only, infected with routine vaccination and infected with booster values were 1,725.6 IU/mL (interquartile range: 684.80- 4,708.9 IU/mL), 2,067.15 IU/mL (interquartile range: 705.33-4,670.4 IU/mL) and 6,139.15 IU/mL (interquartile range: 2,426.05-10,623.40 IU/mL). There was a doubling of antibody titers, from 1,744 IU/mL to 3,829 IU/mL, in those who received a booster versus routine vaccination (p>0.05). The antibodies remained positive more than a year following vaccination.</p>","PeriodicalId":54369,"journal":{"name":"Journal of the Pakistan Medical Association","volume":"75 3","pages":"472-475"},"PeriodicalIF":0.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pakistan Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47391/JPMA.20351","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
The retrospective cohort study was planned to determine long-term anti-spike immunoglobulin G levels after receiving coronavirus disease-2019 vaccination by healthcare workers. The study took place between June and July 2022 at the Indus hospital in Karachi. Healthcare workers who had previously screened negative to prevaccination Severe Acute Respiratory Syndrome Coronavirus 2 nucleocapsid antibodies were tested for post-vaccination Severe Acute Respiratory Syndrome Coronavirus 2 anti-spike immunoglobulin G levels using a quantitative assay. The test was also performed on the stored pre-vaccination samples of the subjects collected up to 18 months previously. Antibody levels in subjects without infection, with infection and with booster administration were compared. The median postvaccination anti-spike immunoglobulin G in infected only, infected with routine vaccination and infected with booster values were 1,725.6 IU/mL (interquartile range: 684.80- 4,708.9 IU/mL), 2,067.15 IU/mL (interquartile range: 705.33-4,670.4 IU/mL) and 6,139.15 IU/mL (interquartile range: 2,426.05-10,623.40 IU/mL). There was a doubling of antibody titers, from 1,744 IU/mL to 3,829 IU/mL, in those who received a booster versus routine vaccination (p>0.05). The antibodies remained positive more than a year following vaccination.
期刊介绍:
Primarily being a medical journal, JPMA publishes scholarly research focusing on the various fields in the areas of health and medical education. It publishes original research describing recent advances in health particularly clinical studies, clinical trials, assessments of pathogens of diagnostic importance, medical genetics and epidemiological studies. Review articles highlighting importance of various issues in the domain of public health, drug research and medical education are also accepted. As a leading journal of South Asia, JPMA remains cognizant of the recent advances in the rapidly growing fields of biomedical sciences, it invites and encourages scholars to write short reviews and invited editorials on the emerging issues. We particularly aim to promote health standards of developing countries by encouraging manuscript submissions on issues affecting the public health and health delivery services.